Skip to main content

Concepció Jacobs Cachá

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Concepció Jacobs Cachá

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Nefrologia i Trasplantament Renal

IP: Oriol Bestard Matamoros
Collaborators: Marina Lopez Martinez, Francesc Moreso Mateos, Natalia Ramos Terrades, Maria Jose Soler Romeo, Joana Sellarés Roig, Pamela Dominguez Baez, Irene Agraz Pamplona, Sheila Bermejo Garcia, Mariona Juvé Torres, Irina Betsabe Torres Rodriguez, Concepció Jacobs Cachá, Elena Isabel Crespo Gimeno, Laura Donadeu Casassas, Carmen Llorens Cebriá, Manel Perelló Carrascosa, Maria Antonia Emilia Meneghini
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 00883
Duration: 01/01/2022 - 30/06/2025

Desentrañando las vías protectoras de los SGLT2i y GLP-1RA en la enfermedad renal diabética: papel de las proteínas adaptadoras MAP17 y D-AKAP-2 en ratones db/db y organoides renales humanos.

IP: Maria Jose Soler Romeo
Collaborators: Mario Alonso Narvaez Barros, Pamela Dominguez Baez, Sheila Bermejo Garcia, Alejandra Planas Vilaseca, Concepció Jacobs Cachá, Juan Carlos León Román, Irene Martinez Diaz
Funding agency: Instituto de Salud Carlos III
Funding: 122210
Reference: PI21/01292
Duration: 01/01/2022 - 30/06/2026

RICORS2040 - Inflamación e inmunopatología de órganos y sistemas

IP: Maria Jose Soler Romeo
Collaborators: Francesc Moreso Mateos, Oriol Bestard Matamoros, Joana Sellarés Roig, Irina Betsabe Torres Rodriguez, Concepció Jacobs Cachá, Maria Antonia Emilia Meneghini
Funding agency: Instituto de Salud Carlos III
Funding: 105765
Reference: RD21/0005/0016
Duration: 01/01/2022 - 31/12/2024

The interplay between ACE2 and AXL systems to predict COVID-19 disease severity and outcomes

IP: Maria Jose Soler Romeo
Collaborators: Concepció Jacobs Cachá
Funding agency: Fundació La Marató de TV3
Funding: 154125
Reference: 202133-30
Duration: 23/09/2021 - 22/09/2024

Related news

The annual event offered a space for dialogue between the scientific community and society on how to address the future of ageing through research and innovation.

Docetaxel, carried by Soluplus, proved to be the most effective and least toxic combination to cross the blood-brain barrier and attack the tumour directly.

Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.

Related professionals

Marc Ribó Jacobi

Marc Ribó Jacobi

Main researcher
Stroke research
Read more
Raquel Maria Lastra Borras

Raquel Maria Lastra Borras

Research technician
Headache and Neurological Pain
Read more
Lara Grau Lopez

Lara Grau Lopez

Psychiatry, Mental Health and Addictions
Read more
Iris Garcia Martínez

Iris Garcia Martínez

Postdoctoral researcher
Transfusional Medicine
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.